Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
Gilead Sciences(GILD) stock is priced at $122.13, giving the company a market capitalization of 152.1B. It carries a P/E multiple of 19.00 and pays a dividend yield of 2.6%.
On 2025-11-06, Gilead Sciences(GILD) shares started trading at $122.20, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 6.71M.
The stock's 52-week range extends from a low of $86.08 to a high of $124.61.
The stock's 52-week range extends from a low of $86.08 to a high of $124.61.
GILD News
Gilead Sciences recently reported strong third-quarter earnings with revenue of US$7.77 billion and net income of US$3.05 billion, raised its 2025 earnings guid...
Maxim Group analyst Michael Okunewitch has maintained their neutral stance on GILD stock, giving a Hold rating on October 31. Elevate Your Investing Strategy: T...
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affe...
Analyst ratings
70%
of 30 ratingsMore GILD News
Gilead Sciences (GILD) released its third-quarter results showing year-over-year gains in both revenue and net income. The company also raised its full-year ear...
Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...
Gilead Sciences ((GILD)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks...
Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13. GILD is in positive territory. Get...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $147 from $143 and keeps an Overweight rating on the shares. Gilead’s FY...
Joseph Stringer, an analyst from Needham, reiterated the Buy rating on Gilead Sciences. The associated price target remains the same with $133.00. Elevate Your...
Wells Fargo raised the firm’s price target on Gilead (GILD) to $145 from $140 and keeps an Overweight rating on the shares. The firm thinks the company’s Q3 was...